Drug Development Dashboard
Introduction & Methodology
Using publicly available data from review documents on Drugs@FDA and information listed in FDA’s public database on post-market requirements (PMRs) we created this dashboard to show how four expedited programs impact the time it takes for a drug or biologic to be approved.
The first dashboard displays data on original therapeutic agents approved for use in oncology since January 2013. Supplemental approvals and supportive agents were excluded. Please note the reviews for some drugs/biologics approved since January 2013 were not yet available online. These approvals were excluded from the dashboard and will be added as their review documents become available.
The new feature on the dashboard highlights data on original and supplemental Accelerated Approvals in oncology between 1992 and 2021. The dashboard can be used to gain insights on the status of Accelerated Approvals, progress made on fulfilling post-market requirements and commitments under Accelerated Approval, as well as details on the endpoints serving as the basis for granting these approvals.
Navigate between the two dashboards by clicking the description boxes at the top of the window.
Reset the dashboard to show all approvals by clicking the “|<-“ on the bottom of the window.
Mouse over the figures on the dashboard for additional details about each approval.
Text and figures on the dashboard can be clicked to change the which approvals are shown. (E.g. click “Response Rate” in the endpoints table to filter all figures on the dashboard to display only those approvals granted Accelerated Approval based on response rate). Click again to reset the filter to show all approvals.
This dashboard was last updated April 2021 and will be updated on a quarterly basis. You are welcome to submit feedback to email@example.com.